Curia
Curia Global, commonly referred to as Curia, is a leading contract research, development, and manufacturing organisation headquartered in the United States. Established in 2019, Curia has rapidly expanded its operational footprint across North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Specialising in drug development and manufacturing, Curia offers a comprehensive suite of services, including analytical testing, formulation development, and commercial manufacturing. What sets Curia apart is its commitment to quality and innovation, ensuring that clients receive tailored solutions that meet stringent regulatory standards. With a strong market presence, Curia has achieved significant milestones, including strategic acquisitions that enhance its capabilities. The company is recognised for its expertise in complex drug modalities, making it a trusted partner for clients seeking to navigate the complexities of drug development.
DitchCarbon Score
How does Curia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Curia's score of 35 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Curia's reported carbon emissions
In 2021, Curia Global, Inc. reported significant carbon emissions totalling approximately 41,290,410 kg CO2e for Scope 1 and about 46,508,720 kg CO2e for Scope 2. This data reflects the company's direct and indirect emissions from its operations, with no reported Scope 3 emissions. Curia has committed to achieving net-zero emissions across all scopes by 2050, as part of its long-term climate strategy. This commitment is aligned with the Science Based Targets initiative (SBTi), which underscores the company's dedication to reducing its carbon footprint in the pharmaceuticals, biotechnology, and life sciences sector. The net-zero commitment was formalised in 2024, indicating a proactive approach to climate action. As Curia continues to develop its sustainability initiatives, it aims to implement effective strategies to reduce its overall emissions and contribute positively to global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 41,290,410 |
| Scope 2 | 46,508,720 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Curia is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
